
[Pharmacopeial Forum Table of Contents](#)

View the current Pharmacopeial Forum (PF) Table of Contents. For older PF tables of contents, [visit our archive](#).

Select from the below links to access PF content. A free resource, PF visitors must create a user name and password.

PF 44(5) Table of Contents Publish date: September 7, 2018

PROPOSED IRA

[Proposed Interim Revision Announcements](#)

NF MONOGRAPHS

[Medium-Chain Triglycerides \(1-Mar-2019\)](#)

IN-PROCESS REVISION

[In-Process Revision](#)

GENERAL CHAPTERS

[<3> Topical and Transdermal Drug Products - Product Quality Tests \(USP42-NF37 2S\)](#)

[<60> Microbiological Examination of Nonsterile Products - Tests for Burkholderia Cepacia Complex \[NEW\] \(USP42-NF37 2S\)](#)

[<81> Antibiotics - Microbial Assays \(USP42-NF37 2S\)](#)

[<601> Inhalation and Nasal Drug Products - Aerosols, Sprays, and Powders - Performance Quality Tests \(USP42-NF37 2S\)](#)

[<771> Ophthalmic Products - Quality Tests \(USP42-NF37 2S\)](#)

[<785> Osmolality and Osmolarity \(USP42-NF37 2S\)](#)

[<797> Pharmaceutical Compounding - Sterile Preparations \(USP42-NF37 2S\)](#)

[TABLE OF CONTENTS](#)

[INTRODUCTION](#)

[ORGANIZATION OF THIS CHAPTER](#)

[RESPONSIBILITY OF COMPOUNDING PERSONNEL](#)

[CSP MICROBIAL CONTAMINATION RISK LEVELS](#)

[PERSONNEL TRAINING AND EVALUATION IN ASEPTIC MANIPULATION SKILLS](#)

[IMMEDIATE-USE CSPs](#)

[SINGLE-DOSE AND MULTIPLE-DOSE CONTAINERS](#)

[HAZARDOUS DRUGS AS CSPs](#)

[RADIOPHARMACEUTICALS AS CSPs](#)

[ALLERGEN EXTRACTS AS CSPs](#)
[VERIFICATION OF COMPOUNDING ACCURACY AND STERILITY](#)
[ENVIRONMENTAL QUALITY AND CONTROL](#)
[SUGGESTED STANDARD OPERATING PROCEDURES \(SOPs\)](#)
[ELEMENTS OF QUALITY CONTROL](#)
[VERIFICATION OF AUTOMATED COMPOUNDING DEVICES \(ACDs\) FOR PARENTERAL NUTRITION COMPOUNDING](#)
[FINISHED PREPARATION RELEASE CHECKS AND TESTS](#)
[STORAGE AND BEYOND-USE DATING](#)
[MAINTAINING STERILITY, PURITY, AND STABILITY OF DISPENSED AND DISTRIBUTED CSPs](#)
[PATIENT OR CAREGIVER TRAINING](#)
[PATIENT MONITORING AND ADVERSE EVENTS REPORTING](#)
[QUALITY ASSURANCE \(QA\) PROGRAM](#)
[ABBREVIATIONS AND ACRONYMS](#)

[GLOSSARY](#)

[APPENDICES](#)

[1. INTRODUCTION AND SCOPE](#)

[2.PERSONNEL QUALIFICATIONS--TRAINING, EVALUATION, AND REQUALIFICATION](#)

[3.PERSONAL HYGIENE AND GARBING](#)

[4.FACILITIES AND ENGINEERING CONTROLS](#)

[5. MICROBIOLOGICAL AIR AND SURFACE MONITORING](#)

[6. CLEANING AND DISINFECTING COMPOUNDING AREAS](#)

[7. EQUIPMENT, SUPPLIES, AND COMPONENTS](#)

[8. STERILIZATION AND DEPYROGENATION](#)

[9. SOPs AND MASTER FORMULATION AND COMPOUNDING RECORDS](#)

[10. RELEASE TESTING](#)

[11. LABELING](#)

[12. ESTABLISHING BEYOND-USE DATES](#)

[13. USE OF CONVENTIONALLY MANUFACTURED PRODUCTS](#)

[14. USE OF CSPs AS COMPONENTS](#)

[15. QUALITY ASSURANCE AND QUALITY CONTROL](#)

[16. CSP STORAGE, HANDLING, PACKAGING, SHIPPING, AND TRANSPORT](#)

[17. DOCUMENTATION](#)

[18. COMPOUNDING ALLERGENIC EXTRACTS](#)

[GLOSSARY](#)

[APPENDICES](#)

[<825> Radiopharmaceuticals - Preparation, Compounding, Dispensing, and Repackaging \[NEW\] \(USP42-NF37 2S\)](#)

[<856> Near-Infrared Spectroscopy \[NEW\] \(USP42-NF37 2S\)](#)

[<857> Ultraviolet-Visible Spectroscopy \(USP42-NF37 2S\)](#)

[<1010> Analytical Data - Interpretation and Treatment \(USP42-NF37 2S\)](#)

[<1071> Rapid Sterility Testing of Short-Life Products - A Risk Based Approach \[NEW\] \(USP42-NF37 2S\)](#)

[<1103> Immunological Test Methods - Enzyme-Linked Immunosorbent Assay \(ELISA\) \(USP42-NF37 2S\)](#)

[<1119> Near-Infrared Spectroscopy \(USP42-NF37 2S\)](#)

[<1136> Packaging and Repackaging - Single-Unit Containers \(USP42-NF37 2S\)](#)

[<1177> Good Packaging Practices \(USP42-NF37 2S\)](#)

[<1227> Validation of Microbial Recovery From Pharmacopeial Articles \(USP42-NF37 2S\)](#)

[<1229.16> Prion Sterilization \[NEW\] \(USP42-NF37 2S\)](#)

[<1236> Solubility Measurements \[NEW\] \(USP42-NF37 2S\)](#)

[<1711> Oral Solid Dosage Forms - Dissolution Testing \[NEW\] \(USP42-NF37 2S\)](#)

REAGENTS, INDICATORS, AND SOLUTIONS

Reagent Specifications

[Aluminum Chloride Hexahydrate \[NEW\] \(USP42-NF37 2S\)](#)

Indicators

[Eriochrome Black T \(USP42-NF37 2S\)](#)

REFERENCE TABLES

Container Specifications

[Container Specifications \[NEW\] \(USP42-NF37 2S\)](#)

Description and Solubility

[Description and Relative Solubility of USP and NF Articles \(USP42-NF37 2S\)](#)

[Description and Solubility - G](#)

USP MONOGRAPHS

[Abacavir, Lamivudine and Zidovudine Tablets \[NEW\] \(USP42-NF37 2S\)](#)

[Arginine \(USP42-NF37 2S\)](#)

[Arginine Hydrochloride \(USP42-NF37 2S\)](#)

[Arginine Hydrochloride Compounded Oral Solution \[NEW\] \(USP42-NF37 2S\)](#)

[Astemizole \(USP42-NF37 2S\)](#)

[Astemizole Tablets \(USP42-NF37 2S\)](#)

[Atovaquone and Proguanil Hydrochloride Tablets \[NEW\] \(USP42-NF37 2S\)](#)

[Atropine Sulfate Tablets \(USP42-NF37 2S\)](#)

[Azatadine Maleate \(USP42-NF37 2S\)](#)

[Azithromycin for Oral Suspension \(USP42-NF37 2S\)](#)

[Baclofen Injection \[NEW\] \(USP42-NF37 2S\)](#)

[Bisoprolol Fumarate \(USP42-NF37 2S\)](#)

[Bisoprolol Fumarate Tablets \(USP42-NF37 2S\)](#)

[Cetylpyridinium Chloride \(USP42-NF37 2S\)](#)

[Chlorambucil Compounded Oral Suspension \[NEW\] \(USP42-NF37 2S\)](#)

[Chloramphenicol Compounded Oral Suspension, Veterinary \[NEW\] \(USP42-NF37 2S\)](#)

[Chlordiazepoxide \(USP42-NF37 2S\)](#)

[Chlordiazepoxide Hydrochloride \(USP42-NF37 2S\)](#)

[Clonidine Hydrochloride Compounded Oral Suspension \[NEW\] \(USP42-NF37 2S\)](#)

[Clozapine \(USP42-NF37 2S\)](#)

[Clozapine Tablets \(USP42-NF37 2S\)](#)

[Dehydrocholic Acid Tablets \(USP42-NF37 2S\)](#)

[Demeclocycline \(USP42-NF37 2S\)](#)

[Demeclocycline Oral Suspension \(USP42-NF37 2S\)](#)

[Demeclocycline Hydrochloride Capsules \(USP42-NF37 2S\)](#)

[Deslanoside \(USP42-NF37 2S\)](#)

[Desmopressin Acetate \(USP42-NF37 2S\)](#)

[Dexamethasone Acetate Injectable Suspension \(USP42-NF37 2S\)](#)

[Dexamethasone Sodium Phosphate Cream \(USP42-NF37 2S\)](#)

[Dexamethasone Sodium Phosphate Ophthalmic Ointment \(USP42-NF37 2S\)](#)
[Dextroamphetamine Sulfate Capsules \(USP42-NF37 2S\)](#)
[Diatrizoate Sodium \(USP42-NF37 2S\)](#)
[Diazepam Capsules \(USP42-NF37 2S\)](#)
[Diazepam Extended-Release Capsules \(USP42-NF37 2S\)](#)
[Dichloralphenazone \(USP42-NF37 2S\)](#)
[Dicloxacillin Sodium for Oral Suspension \(USP42-NF37 2S\)](#)
[Diethylstilbestrol Injection \(USP42-NF37 2S\)](#)
[Diethylstilbestrol Tablets \(USP42-NF37 2S\)](#)
[Diphenhydramine Hydrochloride Oral Powder \[NEW\] \(USP42-NF37 2S\)](#)
[Doxazosin Tablets \(USP42-NF37 2S\)](#)
[Enalapril Maleate \(USP42-NF37 2S\)](#)
[Epinephrine Bitartrate \(USP42-NF37 2S\)](#)
[Ezetimibe \(USP42-NF37 2S\)](#)
[Felodipine \(USP42-NF37 2S\)](#)
[Fenoldopam Mesylate Injection \(USP42-NF37 2S\)](#)
[Hard Gelatin Capsule Shell \(USP42-NF37 2S\)](#)
[Hydrochlorothiazide Compounded Oral Suspension \[NEW\] \(USP42-NF37 2S\)](#)
[Hydrocortisone \(USP42-NF37 2S\)](#)
[Hard Hypromellose Capsule Shell \(USP42-NF37 2S\)](#)
[Levodopa Capsules \(USP42-NF37 2S\)](#)
[Levodopa Tablets \(USP42-NF37 2S\)](#)
[Levofloxacin Tablets \(USP42-NF37 2S\)](#)
[Lidocaine, Racepinephrine and Tetracaine Hydrochlorides Compounded Topical Gel \[NEW\] \(USP42-NF37 2S\)](#)
[Loracarbef \(USP42-NF37 2S\)](#)
[Magnesium Citrate \(USP42-NF37 2S\)](#)
[Memantine Hydrochloride Oral Solution \[NEW\] \(USP42-NF37 2S\)](#)
[Methacholine Chloride \(USP42-NF37 2S\)](#)
[Oxtriphylline Oral Solution \(USP42-NF37 2S\)](#)
[Oxtriphylline Tablets \(USP42-NF37 2S\)](#)
[Oxycodone Hydrochloride Extended-Release Tablets \(USP42-NF37 2S\)](#)
[Oxytetracycline and Nystatin Capsules \(USP42-NF37 2S\)](#)
[Oxytetracycline and Nystatin for Oral Suspension \(USP42-NF37 2S\)](#)
[Oxytetracycline Calcium \(USP42-NF37 2S\)](#)
[Oxytetracycline Calcium Oral Suspension \(USP42-NF37 2S\)](#)
[Phensuximide \(USP42-NF37 2S\)](#)
[Phensuximide Capsules \(USP42-NF37 2S\)](#)
[Phenytoin Compounded Topical Gel \[NEW\] \(USP42-NF37 2S\)](#)
[Physostigmine Salicylate Ophthalmic Solution \(USP42-NF37 2S\)](#)
[Piroxicam \(USP42-NF37 2S\)](#)
[Potassium Perchlorate Capsules \(USP42-NF37 2S\)](#)
[Pregabalin Capsules \[NEW\] \(USP44-NF39 1S\)](#)
[Propoxycaine Hydrochloride \(USP42-NF37 2S\)](#)
[Propylidone Injectable Oil Suspension \(USP42-NF37 2S\)](#)
[Quinine Sulfate Capsules \(USP42-NF37 2S\)](#)
[Repaglinide and Metformin Hydrochloride Tablets \[NEW\] \(USP42-NF37 2S\)](#)
[Rifampin \(USP42-NF37 2S\)](#)
[Rifampin Capsules \(USP42-NF37 2S\)](#)
[Rifampin for Injection \(USP42-NF37 2S\)](#)

[Sodium Fluoride Tablets \(USP42-NF37 2S\)](#)
[Thioridazine Oral Suspension \(USP42-NF37 2S\)](#)
[Timolol Maleate \(USP42-NF37 2S\)](#)
[Torseamide Compounded Oral Suspension \[NEW\] \(USP42-NF37 2S\)](#)
[Tranexamic Acid \(USP42-NF37 2S\)](#)
[Triamcinolone Acetonide Cream \(USP42-NF37 2S\)](#)
[Triamcinolone Acetonide Dental Paste \(USP42-NF37 2S\)](#)
[Vancomycin \(USP42-NF37 2S\)](#)

DIETARY SUPPLEMENT MONOGRAPHS

[Bael Tree Fruit \[NEW\] \(USP42-NF37 2S\)](#)
[Bael Tree Fruit Dry Extract \[NEW\] \(USP42-NF37 2S\)](#)
[Bael Tree Fruit Powder \[NEW\] \(USP42-NF37 2S\)](#)
[Cobamamide \(USP42-NF37 2S\)](#)
[Coptis Species Rhizome \[NEW\] \(USP42-NF37 2S\)](#)
[Coptis Species Rhizome Dry Extract \[NEW\] \(USP42-NF37 2S\)](#)
[Coptis Species Rhizome Powder \[NEW\] \(USP42-NF37 2S\)](#)
[Cystine \(USP42-NF37 2S\)](#)
[Indian Barberry Stem \[NEW\] \(USP42-NF37 2S\)](#)
[Indian Barberry Stem Dry Extract \[NEW\] \(USP42-NF37 2S\)](#)
[Indian Barberry Stem Powder \[NEW\] \(USP42-NF37 2S\)](#)
[Terminalia Chebula Fruit \[NEW\] \(USP42-NF37 2S\)](#)
[Terminalia Chebula Fruit Dry Extract \[NEW\] \(USP42-NF37 2S\)](#)
[Terminalia Chebula Fruit Powder \[NEW\] \(USP42-NF37 2S\)](#)

EXCIPIENTS

Excipients (USP and NF), Listed By Category (USP42-NF37 2S)

[Briefing](#)

[Introduction](#)

[Emulsifying Agent](#)

[Lubricant](#)

NF MONOGRAPHS

[Purified Bentonite \(USP42-NF37 2S\)](#)
[Galactose \(USP42-NF37 2S\)](#)
[Glyceryl Mono and Dicaprylate \[NEW\] \(USP42-NF37 2S\)](#)
[Glyceryl Mono and Dicaprylocaprate \[NEW\] \(USP42-NF37 2S\)](#)
[Glyceryl Monocaprylate \(USP42-NF37 2S\)](#)
[Glyceryl Monocaprylocaprate \(USP42-NF37 2S\)](#)

STAGE 4 HARMONIZATION

[Stage 2 Harmonization](#)

STIMULI TO THE REVISION PROCESS

STIMULI TO THE REVISION PROCESS

Acceptance Sampling Strategies Applied to USP <790> Visible Particulates In Injections